10x Genomics Future Growth

Future criteria checks 1/6

10x Genomics is forecast to grow earnings and revenue by 69.1% and 11.7% per annum respectively. EPS is expected to grow by 67.3% per annum. Return on equity is forecast to be 4.7% in 3 years.

Key information

69.1%

Earnings growth rate

67.3%

EPS growth rate

Life Sciences earnings growth16.3%
Revenue growth rate11.7%
Future return on equity4.7%
Analyst coverage

Good

Last updated27 Feb 2024

Recent future growth updates

Recent updates

Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

Feb 05
Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

10x Genomics: Sales Are Growing At A Rapid Rate, But So Are Expenses

Jan 20

Revenues Tell The Story For 10x Genomics, Inc. (NASDAQ:TXG) As Its Stock Soars 31%

Dec 22
Revenues Tell The Story For 10x Genomics, Inc. (NASDAQ:TXG) As Its Stock Soars 31%

We're Hopeful That 10x Genomics (NASDAQ:TXG) Will Use Its Cash Wisely

Nov 03
We're Hopeful That 10x Genomics (NASDAQ:TXG) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

Aug 04
Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

Why Investors Shouldn't Be Surprised By 10x Genomics, Inc.'s (NASDAQ:TXG) P/S

Jun 04
Why Investors Shouldn't Be Surprised By 10x Genomics, Inc.'s (NASDAQ:TXG) P/S

At US$52.43, Is 10x Genomics, Inc. (NASDAQ:TXG) Worth Looking At Closely?

Apr 29
At US$52.43, Is 10x Genomics, Inc. (NASDAQ:TXG) Worth Looking At Closely?

10x Genomics, Inc. (NASDAQ:TXG) Shares Could Be 28% Below Their Intrinsic Value Estimate

Mar 24
10x Genomics, Inc. (NASDAQ:TXG) Shares Could Be 28% Below Their Intrinsic Value Estimate

We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow

Feb 02
We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow

Is Now The Time To Look At Buying 10x Genomics, Inc. (NASDAQ:TXG)?

Jan 12
Is Now The Time To Look At Buying 10x Genomics, Inc. (NASDAQ:TXG)?

An Intrinsic Calculation For 10x Genomics, Inc. (NASDAQ:TXG) Suggests It's 39% Undervalued

Dec 22
An Intrinsic Calculation For 10x Genomics, Inc. (NASDAQ:TXG) Suggests It's 39% Undervalued

10x Genomics: No Signs Of A Growth Turnaround, Heavy Bearish Momentum

Oct 12

Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

Oct 05
Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

10x Genomics cut to Sell at Goldman Sachs on slower sales ramp

Aug 18

10x Genomics: Still Expensive, No Profitability In Sight, And Insiders Are Still Selling

Jul 30

10x Genomics guides to Q2 revenues below consensus; shares down 13% after hours

Jul 14

Earnings and Revenue Growth Forecasts

NasdaqGS:TXG - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026922-142816910
12/31/2025791-107-617914
12/31/2024679-184-172-1214
12/31/2023619-255-65-15N/A
9/30/2023591-223-113-27N/A
6/30/2023568-172-118-11N/A
3/31/2023536-174-126-17N/A
12/31/2022516-166-165-34N/A
9/30/2022504-167-161-42N/A
6/30/2022498-142-161-58N/A
3/31/2022499-89-129-38N/A
12/31/2021490-58-123-21N/A
9/30/2021459-455-253-157N/A
6/30/2021406-504-264-187N/A
3/31/2021333-533-289-219N/A
12/31/2020299-543-256-218N/A
9/30/2020262-134-104-81N/A
6/30/2020251-78-46-11N/A
3/31/2020264-49-1923N/A
12/31/2019246-31-835N/A
9/30/2019221-100-62-23N/A
6/30/2019197-105-69-43N/A
3/31/2019170-105-71-57N/A
12/31/2018146-112-83-76N/A
12/31/201771-19-14-11N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: TXG is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TXG is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TXG is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: TXG's revenue (11.7% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: TXG's revenue (11.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: TXG's Return on Equity is forecast to be low in 3 years time (4.7%).


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.